Inhibition of TRPC6/Ca2+ signalling either pharmacologically (using SKF-96365) or by genetic downregulation using siRNA showed a significant reduction in A549 cell (an in vitro model of NSCLC) proliferation by arresting the cell cycle at the S-G2/M phase and invasion [89]. The gene discussed is TRPC6; the disease is non-small cell lung carcinoma.